Argen X NV/ NL0010832176 /
2024-09-05 8:52:14 PM | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
525.6012USD | - | 61 Turnover: 32,277.6552 |
-Bid Size: - | -Ask Size: - | 31.88 bill.USD | - | - |
GlobeNewswire
07-25
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
GlobeNewswire
07-18
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 202...
GlobeNewswire
07-16
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Ge...
GlobeNewswire
06-25
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire
06-21
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropat...
GlobeNewswire
06-17
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcomi...
GlobeNewswire
05-09
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-02
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
GlobeNewswire
04-16
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...
GlobeNewswire
03-27
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
GlobeNewswire
03-26
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...
GlobeNewswire
03-07
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...
GlobeNewswire
02-29
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
GlobeNewswire
02-22
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...
GlobeNewswire
02-20
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...